{
    "id": 27355,
    "fullName": "ASPH over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "ASPH over exp indicates an over expression of the Asph protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 444,
        "geneSymbol": "ASPH",
        "terms": [
            "ASPH",
            "AAH",
            "BAH",
            "CASQ2BP1",
            "FDLAB",
            "HAAH",
            "JCTN",
            "junctin"
        ]
    },
    "variant": "over exp",
    "createDate": "01/02/2018",
    "updateDate": "01/02/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 12620,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MO-I-1151 delayed growth and progression of tumors in cholangiocarcinoma xenografts with Asph overexpression (PMID: 26954680).",
            "molecularProfile": {
                "id": 28790,
                "profileName": "ASPH over exp"
            },
            "therapy": {
                "id": 6545,
                "therapyName": "MO-I-1151",
                "synonyms": null
            },
            "indication": {
                "id": 4947,
                "name": "cholangiocarcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10489,
                    "pubMedId": 26954680,
                    "title": "Anti-Tumor Effects of Second Generation \u03b2-Hydroxylase Inhibitors on Cholangiocarcinoma Development and Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26954680"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 12619,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MO-I-1100 inhibited Notch signaling and growth of tumors in xenograft and cell line models of hepatocellular carcinoma with Asph overexpression (PMID: 24954865).",
            "molecularProfile": {
                "id": 28790,
                "profileName": "ASPH over exp"
            },
            "therapy": {
                "id": 6544,
                "therapyName": "MO-I-1100",
                "synonyms": null
            },
            "indication": {
                "id": 684,
                "name": "hepatocellular carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10500,
                    "pubMedId": 24954865,
                    "title": "A cell-surface \u03b2-hydroxylase is a biomarker and therapeutic target for hepatocellular carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24954865"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 28790,
            "profileName": "ASPH over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}